Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Serotonin-Norepinephrine reuptake inhibitors
13 evidence topics · 9 sources
NICE guideline: an alternative SSRI or an SNRI after sertraline
CANMAT guideline: duloxetine and venlafaxine XR as first-line agents
“an SNRI such as duloxetine or venlafaxine XR, or other antidepressant such as agomelatine.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In head-to-head comparisons, the efficacy of SSRIs and SNRIs appear to be similar” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Some data suggest that escitalopram may be less effective than venlafaxine XR” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Efficacy of venlafaxine was similar to pregabalin in one RCT” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“If response to optimal doses is inadequate or the agent is not tolerated, therapy should be switched to another first-line agent before considering second-line medications.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
BAP guideline: SNRIs as alternative initial treatments
FDA-approved GAD indication: venlafaxine extended-release
Venlafaxine extended-release: HAM-A results of the four adult GAD studies
| Study and treatment group | LS mean change from baseline (SE) | Placebo-subtracted difference (95% CI) |
|---|---|---|
| Study 1, venlafaxine XR 75 mg | “-11.1 (0.95)” | “-1.5 (-3.8, 0.8)” |
| Study 1, venlafaxine XR 150 mg | “-11.7 (0.87)” | “-2.2 (-4.5, 0.1)” |
| Study 1, venlafaxine XR 225 mg | “-12.1 (0.81)” | “-2.6 (-4.9, -0.3)” |
| Study 1, placebo | “-9.5 (0.85)” | |
| Study 2, venlafaxine XR 75 mg | “-10.6 (0.82)” | “-2.6 (-4.6, -0.5)” |
| Study 2, venlafaxine XR 150 mg | “-9.8 (0.86)” | “-1.7 (-3.8, 0.3)” |
| Study 2, placebo | “-8.0 (0.73)” | |
| Study 3, venlafaxine XR 37.5 mg | “-13.8” | “-2.8 (-5.1, -0.6)” |
| Study 3, venlafaxine XR 75 mg | “-15.5” | “-4.6 (-6.9, -2.3)” |
| Study 3, venlafaxine XR 150 mg | “-16.4” | “-5.5 (-7.8, -3.1)” |
| Study 3, placebo | “-11.0” | |
| Study 4, venlafaxine XR 75-225 mg | “-13.4 (0.79)” | “- 4.7 (-6.6, -2.9)” |
| Study 4, placebo | “-8.7 (0.70)” |
FDA-approved GAD indication: duloxetine
Duloxetine: relapse prevention in responders
FDA approval history and response and remission with venlafaxine and duloxetine
“Venlafaxine is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) that is FDA-approved for the treatment of GAD, MDD, panic disorder, and social anxiety disorder.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In adults with GAD, venlafaxine (75–225 mg/day) effectively reduces anxiety symptoms” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“and was the first FDA-approved antidepressant for the treatment of GAD in this age group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Response rates in patients receiving venlafaxine XR were 69% compared to 46% in patients randomized to placebo (p<0.001)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These trials have recently been subjected to a meta-analysis which revealed superior remission rates for duloxetine (n=2,399, RR = 1.60, 95% CI: 1.43–1.80) and greater improvement in HAM-A scores (n=1,135, MD = 3.34, 95% CI: 2.37–4.32), while finding no differences in discontinuation rates between placebo and duloxetine” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Network meta-analysis: duloxetine and venlafaxine
“Duloxetine (MD -3·13, 95% credible interval [CrI] -4·13 to -2·13)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“venlafaxine (MD -2·69, 95% CrI -3·50 to -1·89)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“were more efficacious than placebo with relatively good acceptability.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
SNRIs compared with SSRIs: efficacy and sexual adverse effects
“SNRIs are very similar to SSRIs in their mechanism of action, side effects, and efficacy rates (Hedges’ g = 0.42, SD=0.12, p<0.0001)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“though there is some evidence that SNRIs are associated with less sexual dysfunction side effects than SSRIs” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adverse reactions and discontinuation with venlafaxine extended-release
Adverse reactions and discontinuation with duloxetine
Relapse after discontinuation: meta-analysis of relapse prevention trials, SNRI subgroup
| Subgroup | Number of studies | Odds ratio of relapse, placebo relative to continued antidepressant (95% CI) |
|---|---|---|
| SNRI | “3”View highlighted excerpt for this quote | “5.03 (1.31 to 19.40)”View highlighted excerpt for this quote |